CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the 18th Annual European Life Sciences CEO Forum in Zurich, Switzerland.
The company's CEO, John Climaco, will deliver a presentation on Wednesday, February 26, 2025, at 3:20 PM CET / 9:20 AM EST. Management will also be available for one-on-one meetings with qualified registered investors during the conference.
A video webcast of the presentation will be accessible on-demand through the conference presenters portal for registered attendees. The presentation represents an opportunity for CNS Pharmaceuticals to showcase its developments in primary and metastatic cancer treatments.
CNS Pharmaceuticals (NASDAQ:CNSP), un'azienda biofarmaceutica focalizzata sullo sviluppo di nuovi trattamenti per i tumori cerebrali e del sistema nervoso centrale, ha annunciato la sua partecipazione al 18° Forum Annuale dei CEO delle Scienze della Vita in Europa a Zurigo, Svizzera.
Il CEO dell'azienda, John Climaco, terrà una presentazione mercoledì 26 febbraio 2025, alle 15:20 CET / 9:20 EST. La direzione sarà inoltre disponibile per incontri individuali con investitori registrati qualificati durante la conferenza.
Un webcast video della presentazione sarà accessibile on-demand attraverso il portale dei relatori della conferenza per i partecipanti registrati. La presentazione rappresenta un'opportunità per CNS Pharmaceuticals di mostrare i suoi sviluppi nei trattamenti per il cancro primario e metastatico.
CNS Pharmaceuticals (NASDAQ:CNSP), una compañía biofarmacéutica centrada en el desarrollo de nuevos tratamientos para los cánceres del cerebro y del sistema nervioso central, ha anunciado su participación en el 18º Foro Anual de CEO de Ciencias de la Vida de Europa en Zúrich, Suiza.
El CEO de la compañía, John Climaco, realizará una presentación el miércoles 26 de febrero de 2025, a las 3:20 PM CET / 9:20 AM EST. La dirección también estará disponible para reuniones individuales con inversores registrados calificados durante la conferencia.
Una transmisión en video de la presentación estará disponible bajo demanda a través del portal de presentadores de la conferencia para los asistentes registrados. La presentación representa una oportunidad para que CNS Pharmaceuticals muestre sus desarrollos en tratamientos para el cáncer primario y metastásico.
CNS Pharmaceuticals (NASDAQ:CNSP), 뇌 및 중추 신경계 암 치료를 위한 새로운 치료법 개발에 중점을 둔 생명공학 회사가 스위스 취리히에서 열리는 제18회 유럽 생명 과학 CEO 포럼에 참여한다고 발표했습니다.
회사의 CEO인 John Climaco는 2025년 2월 26일 수요일, CET 오후 3시 20분 / EST 오전 9시 20분에 발표를 할 예정입니다. 경영진은 또한 회의 동안 자격을 갖춘 등록 투자자와의 일대일 미팅을 위해 대기할 것입니다.
발표의 비디오 웹캐스트는 등록된 참석자를 위한 회의 발표자 포털을 통해 주문형으로 접근할 수 있습니다. 이 발표는 CNS Pharmaceuticals가 주요 및 전이성 암 치료에 대한 개발 사항을 선보일 수 있는 기회를 제공합니다.
CNS Pharmaceuticals (NASDAQ:CNSP), une entreprise biopharmaceutique axée sur le développement de nouveaux traitements pour les cancers du cerveau et du système nerveux central, a annoncé sa participation au 18e Forum Annuel des PDG des Sciences de la Vie en Europe à Zurich, en Suisse.
Le PDG de l'entreprise, John Climaco, fera une présentation le mercredi 26 février 2025, à 15h20 CET / 9h20 EST. La direction sera également disponible pour des réunions individuelles avec des investisseurs enregistrés qualifiés pendant la conférence.
Un webinaire vidéo de la présentation sera accessible à la demande via le portail des présentateurs de la conférence pour les participants enregistrés. La présentation représente une occasion pour CNS Pharmaceuticals de mettre en avant ses avancées dans les traitements des cancers primaires et métastatiques.
CNS Pharmaceuticals (NASDAQ:CNSP), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuartiger Behandlungen für Gehirn- und zentrale Nervensystemtumoren konzentriert, hat seine Teilnahme am 18. jährlichen CEO-Forum für Lebenswissenschaften in Europa in Zürich, Schweiz, angekündigt.
Der CEO des Unternehmens, John Climaco, wird am Mittwoch, den 26. Februar 2025, um 15:20 Uhr CET / 9:20 Uhr EST eine Präsentation halten. Das Management wird während der Konferenz auch für persönliche Gespräche mit qualifizierten registrierten Investoren zur Verfügung stehen.
Ein Video-Webcast der Präsentation wird für registrierte Teilnehmer über das Portal der Konferenzreferenten auf Abruf verfügbar sein. Die Präsentation bietet CNS Pharmaceuticals die Möglichkeit, seine Entwicklungen in der Behandlung von primären und metastatischen Krebserkrankungen zu präsentieren.
- None.
- None.
Webcast presentation Wednesday, February 26th at 3:20 PM CET
HOUSTON, TX / ACCESS Newswire / February 20, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the 18th Annual European Life Sciences CEO Forum on Wednesday, February 26, 2025 at 3:20 PM CET / 9:20 AM EST in Zurich, Switzerland.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.
A video webcast of the presentation will be available on-demand for those registered to attend the event and can be accessed through the conference presenters portal.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
The Company's second drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. Similar to Berubicin, TPI 287 has shown the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 has been well tolerated in over 350 patients to date, including in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of recurrent glioblastoma, neuroblastoma and medulloblastoma, as well as refractory prostate cancer and melanoma, and in tauopathy disease, which can result in dementia.
For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
When is CNS Pharmaceuticals (CNSP) presenting at the European Life Sciences CEO Forum 2025?
How can investors access CNSP's presentation at the European Life Sciences CEO Forum?
What type of meetings will CNSP management offer at the European Life Sciences CEO Forum?
What is the focus of CNS Pharmaceuticals' (CNSP) research and development?
